Target intelligence / Profile preview

Lysine-specific histone demethylase 5B (KDM5B)

Target
KDM5B
Molecular classification
Enzyme, Histone demethylase, Jumonji C-domain-containing protein, Epigenetic regulator, Chromatin modifier
01

Overview

Lysine-specific histone demethylase 5B (KDM5B), also known as JARID1B or PLU-1, is a chromatin-modifying enzyme that specifically demethylates tri-, di-, and mono-methylated lysine 4 on histone H3 (H3K4) via an oxidative reaction requiring Fe²⁺ and α-ketoglutarate as cofactors[1][7][9]. KDM5B contains a catalytic jumonji C (JmjC) domain, an ARID DNA-binding domain, plant homeodomain fingers, and a zinc-finger motif, reflecting its multifaceted role in interpreting and modifying chromatin states[1][5]. By removing H3K4 methylation, KDM5B typically represses transcription and has essential roles in cell cycle progression, differentiation, and stem cell renewal. It is overexpressed in multiple cancers, where it contributes to tumor initiation, progression, invasion, and metastasis. Its status as an epigenetic modifier and emerging cancer target has led to the development of experimental inhibitors as potential anticancer agents[1][5][7][9].

Other names
JARID1BPLU-1histone demethylase JARID1Bhistone H3 lysine-4 demethylaseKDM5B
02

Mechanism of action

Inhibition of demethylase activity on H3K4me3/me2 marks leading to altered transcription and potential re-expression of tumor suppressor genes

03

Biological functions

Epigenetic regulationTranscriptional repressionCell differentiationStem cell self-renewalCell proliferationRegulation of cell cycle (G1/S and G2/M transitions)Maintenance of genome integrity
04

Disease associations

Cancer (including breast, bladder, lung, prostate, and other tumors)Tumor progression and metastasisPrognostic marker for cancerPotential involvement in developmental disorders
05

Safety considerations

Potential effects on normal stem cell function and tissue homeostasis due to role in cell differentiation and proliferationUnintended effects on global chromatin structure and gene expression
06

Interacting drugs

Experimental small-molecule KDM5B inhibitors (no approved drugs; several under investigation for oncology)
07

Biomarkers

KDM5B expression level (as a cancer biomarker and for prognosis in solid tumors)H3K4 methylation status (as downstream functional biomarker)Not widely used as a companion diagnostic yet, but under research as an efficacy biomarker in tumors

Beyond the preview

Go deeper on Lysine-specific histone demethylase 5B (KDM5B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lysine-specific histone demethylase 5B (KDM5B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call